New Treatments in Pancreatic Ductal Adenocarcinoma
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".
Deadline for manuscript submissions: closed (31 October 2024) | Viewed by 6581
Special Issue Editor
Special Issue Information
Dear Colleagues,
Pancreatic ductal adenocarcinoma (PDAC) continues to increase in incidence; however, survival remains dismal. A large percentage of patients are diagnosed at a late stage when surgery is not technically feasible, leaving few treatment options. A lack of reliable methods of early detection and its therapeutic resistance makes it one of the most highly lethal malignancies. New treatment strategies are being investigated which may ultimately improve the prognosis of pancreatic cancer and potentially convert later-stage patients to having a resectable disease. New treatments for pancreatic cancer are aided by improvements in radiologic imaging, analysis and manipulation of the tumor microenvironment, genomic diagnostics, understanding of pancreatic tumor biology and advances in surgical techniques.
In this Special Issue of Current Oncology, we invite authors to submit work focusing on new treatments in PDAC. Original articles, as well as review articles focusing on advances in radiologic, medical, surgical, and radiation therapy for pancreatic cancer are welcome.
I look forward to hearing from you.
Dr. Kelly J. Lafaro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- novel treatments
- novel therapies
- targeted therapies
- immune therapy
- vaccine therapy
- pancreatic ductal adenocarcinoma
- pancreatic surgery
- chemotherapy for pancreatic cancer
- surgery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.